Thyroid Function Screening & Dysfunction in Patients with Heart Failure: An Examination of Practice at the University of Kentucky Albert B. Chandler Hospital From 2007-2017 by Hall, Alexandra Paige
University of Kentucky 
UKnowledge 
Theses and Dissertations--Public Health (M.P.H. 
& Dr.P.H.) College of Public Health 
2019 
Thyroid Function Screening & Dysfunction in Patients with Heart 
Failure: An Examination of Practice at the University of Kentucky 
Albert B. Chandler Hospital From 2007-2017 
Alexandra Paige Hall 
University of Kentucky, alexandra.hall@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/cph_etds 
 Part of the Public Health Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Hall, Alexandra Paige, "Thyroid Function Screening & Dysfunction in Patients with Heart Failure: An 
Examination of Practice at the University of Kentucky Albert B. Chandler Hospital From 2007-2017" 
(2019). Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.). 255. 
https://uknowledge.uky.edu/cph_etds/255 
This Graduate Capstone Project is brought to you for free and open access by the College of Public Health at 
UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Public Health (M.P.H. & Dr.P.H.) by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
STUDENT AGREEMENT: 
I represent that my capstone and abstract are my original work. Proper attribution has been 
given to all outside sources. I understand that I am solely responsible for obtaining any needed 
copyright permissions. I have obtained needed written permission statement(s) from the 
owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic 
distribution (if such use is not permitted by the fair use doctrine) which will be submitted to 
UKnowledge as Additional File. 
I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and 
royalty-free license to archive and make accessible my work in whole or in part in all forms of 
media, now or hereafter known. I agree that the document mentioned above may be made 
available immediately for worldwide access unless an embargo applies. 
I retain all other ownership rights to the copyright of my work. I also retain the right to use in 
future works (such as articles or books) all or part of my work. I understand that I am free to 
register the copyright to my work. 
REVIEW, APPROVAL AND ACCEPTANCE 
The document mentioned above has been reviewed and accepted by the student’s advisor, on 
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of 
the program; we verify that this is the final, approved version of the student’s capstone including 
all changes required by the advisory committee. The undersigned agree to abide by the 
statements above. 
Alexandra Paige Hall, Student 
Dr. Steven Browning, Committee Chair 
Dr. Sarah Wackerbarth, Director of Graduate Studies 
 1 
 
Thyroid Function Screening & Dysfunction in Patients 
with Heart Failure: An Examination of Practice at the 
University of Kentucky Albert B. Chandler Hospital 
From 2007-2017 
 
 
CAPSTONE PROJECT PAPER 
 
 
A paper submitted in partial fulfillment of the  
requirements for the degree of  
Master of Public Health  
- University of Kentucky College of Public Health – 
 
 
By 
Alexandra Paige Hall, BA 
Lexington, Kentucky 
April 17, 2019 
 
 
 
 
Committee Members 
 
 
_______________________________ 
Steven Browning, PhD, Chair 
 
 
_______________________________ 
Daniela Claudia Moga, MD, PhD 
 
 
_______________________________ 
Anna Kucharska-Newton, PhD, MPH 
 
 
_______________________________ 
Roberto Cardarelli, DO, MHA, MPH 
 2 
Table of Contents 
ABSTRACT ................................................................................................................................ 4 
INTRODUCTION: ........................................................................................................................... 4 
OBJECTIVES: ............................................................................................................................... 4 
METHODS: ................................................................................................................................. 4 
RESULTS: .................................................................................................................................... 4 
INTRODUCTION ....................................................................................................................... 6 
STUDY OBJECTIVES ....................................................................................................................... 6 
CARDIOVASCULAR DISEASE AND HEART FAILURE ................................................................................ 6 
1.1 A BRIEF INTRODUCTION TO CARDIOVASCULAR DISEASE .................................................................. 6 
1.2 HEART FAILURE: AN OVERVIEW ................................................................................................. 7 
1.3 THE BURDEN OF HEART FAILURE ................................................................................................ 7 
THYROID DYSFUNCTION ................................................................................................................ 8 
2.1 A BRIEF INTRODUCTION TO THYROID FUNCTION ........................................................................... 8 
2.2 THYROID DYSFUNCTION: BASICS ................................................................................................ 8 
2.3 THYROID DYSFUNCTION: DIAGNOSTIC DEFINITIONS ....................................................................... 9 
REFERENCE TABLE 1: CHARACTERIZATION OF THYROID DYSFUNCTION: TYPICAL THYROID FUNCTION TESTS ... 11 
2.4 THYROID DYSFUNCTION: INCIDENCE & PREVALENCE .................................................................... 11 
2.5 THYROID DYSFUNCTION SCREENING ......................................................................................... 12 
2.6 CONCLUSION ....................................................................................................................... 13 
LITERATURE REVIEW .............................................................................................................. 13 
3.1 HISTORICAL INVESTIGATION OF THYROID FUNCTION & CARDIOVASCULAR HEALTH ............................. 13 
3.2 THYROID HORMONES & CARDIOVASCULAR PHYSIOLOGY .............................................................. 14 
3.3 THYROID DYSFUNCTION & CARDIOVASCULAR HEALTH .................................................................. 15 
3.4 SUBCLINICAL THYROID DYSFUNCTION & CARDIOVASCULAR HEALTH ................................................ 15 
3.5 THYROID DYSFUNCTION IN HEART FAILURE ................................................................................ 16 
3.6 THYROID SCREENING IN HEART FAILURE PATIENTS ....................................................................... 16 
3.7 CONCLUSION ....................................................................................................................... 17 
METHODS .............................................................................................................................. 17 
4.1 SETTING ............................................................................................................................. 17 
4.2 STUDY DESIGN & SAMPLING ................................................................................................... 18 
4.3 VARIABLES & ENDPOINTS ....................................................................................................... 19 
REFERENCE TABLE 2: NORMAL RANGE (AGE-BASED) FOR THYROID FUNCTION TESTS USED IN THIS STUDY .... 20 
4.4 DATA CLEANING ................................................................................................................... 20 
4.5 ANALYSIS ............................................................................................................................ 21 
 3 
RESULTS ................................................................................................................................ 22 
5.1 FINAL DATA SET ................................................................................................................... 22 
5.2 OVERALL ENCOUNTER CHARACTERISTICS ................................................................................... 24 
5.3 THYROID FUNCTION SCREENING .............................................................................................. 24 
5.4 THYROID DYSFUNCTION ......................................................................................................... 25 
DISCUSSION ........................................................................................................................... 26 
6.1 INTRODUCTION .................................................................................................................... 26 
6.2 FREQUENCY OF THYROID FUNCTION SCREENING .......................................................................... 27 
6.3 THYROID DYSFUNCTION AMONG SCREENED PATIENTS .................................................................. 28 
6.4 LIMITATIONS: POPULATION, CHARACTERISTICS/MEASUREMENTS, ANALYSIS ...................................... 30 
6.5 FURTHER COMMENTS ............................................................................................................ 32 
6.6 NEXT STEPS ......................................................................................................................... 34 
6.7 CONCLUSIONS ...................................................................................................................... 34 
APPENDIX .............................................................................................................................. 36 
TABLE 1. CHARACTERISTICS OF ADULT PATIENTS DURING FIRST KNOWN HOSPITAL ADMISSION WITH 
DOCUMENTATION OF HEART FAILURE AT THE UNIVERSITY OF KENTUCKY ALBERT B. CHANDLER HOSPITAL FROM 
2007-2017 .............................................................................................................................. 36 
TABLE 2. BIVARIATE ANALYSIS OF PATIENT ENCOUNTER CHARACTERISTICS AND THYROID SCREENING FOR 
ADULT PATIENTS DURING FIRST KNOWN HOSPITAL ADMISSION WITH DOCUMENTATION OF HEART FAILURE AT 
THE UNIVERSITY OF KENTUCKY ALBERT B. CHANDLER HOSPITAL FROM 2007-2017 ................................. 37 
TABLE 4. LOGISTIC REGRESSION OF PATIENT CHARACTERISTICS FOR THYROID FUNCTION SCREENING AMONG 
ADULT PATIENTS DURING FIRST KNOWN HOSPITAL ADMISSION WITH DOCUMENTATION OF HEART FAILURE AT 
THE UNIVERSITY OF KENTUCKY ALBERT B. CHANDLER HOSPITAL FROM 2007-2017 ................................. 40 
TABLE 5. LOGISTIC REGRESSION OF PATIENT CHARACTERISTICS FOR THYROID DYSFUNCTION AMONG ADULT 
PATIENTS SCREENED FOR THYROID DYSFUNCTION DURING FIRST KNOWN HOSPITAL ADMISSION WITH 
DOCUMENTATION OF HEART FAILURE AT THE UNIVERSITY OF KENTUCKY ALBERT B. CHANDLER HOSPITAL FROM 
2007-2017 .............................................................................................................................. 41 
FIGURE 2. THYROID FUNCTION TESTING OVER TIME FOR ADULT PATIENTS DURING FIRST KNOWN HOSPITAL 
ADMISSION WITH DOCUMENTATION OF HEART FAILURE AT THE UNIVERSITY OF KENTUCKY ALBERT B. 
CHANDLER HOSPITAL FROM 2007-2017 ........................................................................................ 42 
FIGURE 3. SPECIFIC THYROID FUNCTION STUDIES PERFORMED ON ADULT PATIENTS SCREENED FOR THYROID 
DYSFUNCTION DURING FIRST KNOWN HOSPITAL ADMISSION WITH DOCUMENTATION OF HEART FAILURE AT 
THE UNIVERSITY OF KENTUCKY ALBERT B. CHANDLER HOSPITAL FROM 2007-2017 ................................. 43 
FIGURE 4. THYROID DYSFUNCTION DETECTED AMONG THOSE PATIENTS SCREENED FOR THYROID DYSFUNCTION 
DURING FIRST KNOWN HOSPITAL ADMISSION WITH DOCUMENTATION OF HEART FAILURE AT THE UNIVERSITY 
OF KENTUCKY ALBERT B. CHANDLER HOSPITAL FROM 2007-2017 ....................................................... 44 
ACKNOWLEDGEMENTS .......................................................................................................... 46 
BIOGRAPHICAL SKETCH .......................................................................................................... 47 
 4 
REFERENCES .......................................................................................................................... 48 
 
Abstract 
Introduction: Heart failure constitutes a global pandemic affecting at least 26 million globally 
(an estimated 5.7 million of which are Americans), and its burden on our healthcare system is 
projected to increase.[1]  As a result, it is imperative that diagnostics and treatment among 
that population be evidence based in order to contain costs and optimize patient outcomes. 
Over the last 20 years, thyroid function screening has been recommended for patients upon 
initial diagnosis of heart failure by the American College of Cardiology and other professional 
organizations. However, it remains unclear whether this recommendation is followed by 
practitioners and how much thyroid dysfunction screening uncovers. The aim of this 
capstone is to examine the association between thyroid dysfunction and heart failure and 
explore a practical example of thyroid function evaluation for patients newly-diagnosed with 
that disease.  
Objectives: The primary objective of this study is to explore one medical center’s 
hospitalizations associated with incident heart failure and determine how often and in which 
patients thyroid function is screened (using TSH). A secondary objective was to determine 
the amount of thyroid dysfunction discovered through that screening.  
Methods: Participants in the current study were sampled from inpatient electronic medical 
records for patients at the University of Kentucky Albert B. Chandler Hospital from 2007-
2017. Only first hospitalizations during which heart failure was documented were included in 
the study (N = 15900). Logistic regression was used to analyze the association between 
patient characteristics and the probability of receiving thyroid function screening during that 
hospital stay. Similar analysis was done to explore the association between patient 
characteristics and thyroid dysfunction among those screened. 
Results: A minority (36.09%) of our patient population had their TSH tested during initial 
heart failure admission. In multivariable analysis, longer length of stay (OR: 1.33-2.18), year 
of encounter (OR: 1.03, 95% CI: 1.02-1.04), and female sex (OR: 1.29, 95% CI: 1.21-1.38) were 
significantly associated with increased odds of patients having their TSH tested. Among those 
tested, multivariate analysis revealed that female sex (OR: 1.34, 95% CI: 1.19-2.07) and 
longer length of stay (OR: 1.20 for 8-14 days; OR: 1.45 for 22+ days) were associated with 
increased odds of thyroid dysfunction (abnormal TSH). African American race [vs white], on 
the other hand, was associated with decreased odds of thyroid dysfunction (OR: 0.74, 95% 
CI: 0.59-0.93). Age 65+ was also associated with decreased odds of dysfunction (OR: 0.82, 
95% CI: 0.67-0.998). Of all patients tested, 28% had thyroid dysfunction. The most common 
abnormality detected was high TSH with normal FT4 (11%).  
Conclusion: This study suggested that, despite recommendations, only a minority of newly 
diagnosed heart failure patients who are hospitalized have their thyroid function screened. 
Furthermore, our data hint that thyroid function is not consistently tested on all heart failure 
patients but is tested more often in women and in patients with longer hospitalizations. 
Among those screened, thyroid dysfunction appeared to be more common than that 
reported in the general population but was still a minority of patients. The most common 
abnormality detected was subclinical hypothyroidism. We hope that knowing how often 
thyroid screening is performed, who specifically is screened, and what testing uncovers may 
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lead to more targeted, cost-effective screening in those who would derive the most benefit 
from that practice.  
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Introduction 
This introduction outlines the study’s objectives; provides background 
information on heart failure and thyroid dysfunction; offers current knowledge of the 
pathophysiology, the mechanisms, and the cardiovascular impact of the different stages 
of thyroid dysfunction in heart failure patients; and presents information on the 
recommendations for thyroid dysfunction screening.[2] 
Study Objectives 
The primary objective of this study is to explore one medical center’s incident 
heart failure hospitalizations and determine how often and in which patients thyroid 
function is screened using Thyroid Stimulating Hormone (TSH).  We hypothesize that a 
minority of patients will have their thyroid function checked during their initial heart 
failure hospitalization, that screening will not be uniform for the entire population 
(screening will be more common in patients with certain characteristics), and that thyroid 
function testing increases with time. A secondary objective was to determine the amount 
of thyroid dysfunction discovered through that screening. We hypothesize that 
dysfunction is more common in heart failure patients than in the general population. 
Cardiovascular Disease and Heart Failure 
1.1 A Brief Introduction to Cardiovascular Disease 
Over the last decade, cardiovascular disease (CVD) has become the leading cause 
of death worldwide.[3]  As more countries progress through the epidemiologic transition 
to the final stages to Degenerative/Man-Made and Delayed Degenerative Disease, the 
global burden of cardiovascular disease increases. Over 17 million deaths are attributable 
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to CVD each year—nearly a third of all deaths.[4]  CVD also confers a heavy burden in 
terms of morbidity. CVD was responsible for over 365 million disability-adjusted life-years 
(DALYs) lost in 2017 alone.[4] These data represent increases in both absolute numbers 
and percentages of DALYs compared with 2015 estimates (355 million DALYs).[4] 
1.2 Heart Failure: An Overview 
Heart failure is a complex clinical syndrome characterized by impaired heart 
function (whether from filling or pumping). Risk factors for heart failure are varied and 
include myocarditis, valvular heart disease, tachycardia, diabetes mellitus, structural 
heart disease related to congenital heart disease, sleep apnea, excessive drug or alcohol 
use, obesity, and CVD (in particular, ischemic heart disease), which confers the highest 
risk of heart failure.[5, 6]  Heart failure is a global pandemic affecting at least 26 million 
globally (an estimated 6.2 million of which are Americans).[1, 7]  And the problem is 
growing—partly as a result of advances in treatment, demographic change (prevalence 
rises exponentially with age and affects 4% to 8% of people older than 65), and improved 
survival.[5]  While incidence rates have reached a relative plateau, prevalence continues 
to rise.[8]  In the US alone, it is estimated that heart failure prevalence will increase 46% 
from 2012- 2030.[9]  
1.3 The Burden of Heart Failure 
Unlike some non-communicable conditions that are largely managed in an 
outpatient setting (hyperlipidemia, for example), heart failure’s burden is recurrent 
(characterized by a relapsing pattern), and the associated healthcare costs fall heavily on 
the hospital system.[10]  In some areas of the United States, annual hospital readmission 
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rates are estimated to be as high as 50%.[11]  In 2014 alone, 900,000 hospital discharges 
listed heart failure as the primary diagnosis.[7]  
Thyroid Dysfunction 
2.1 A Brief Introduction to Thyroid Function 
The thyroid gland is an endocrine organ tasked with producing hormones that 
regulate a multitude of metabolic functions in the human body. Among others, thyroid 
hormones play a key role in growth, neuronal development, reproduction, and regulation 
of energy metabolism.[12]  Consequently, defects in the formation of the thyroid, 
production of its hormones, or release of the same can contribute to a variety of adverse 
health effects. The thyroid gland secretes two primary hormones, T3 
(3,5,3ʹ-triiodothyronine—the more biologically active hormone) and T4 
(3,5,3ʹ,5ʹ-tetraiodothyronine; also known as thyroxine).[13]  These hormones mediate 
their multitude of effects via nuclear hormone receptors.  
2.2 Thyroid Dysfunction: Basics 
Thyroid dysfunction (a general term that encompasses both deficiency as well as 
overabundance of thyroid hormones) is common around the world and can have 
potentially devastating health consequences. While deficiency of iodine (an integral 
component of thyroid hormones) is reportedly the  most common cause of thyroid 
disorders, dysfunction remains common in ‘iodine sufficient’ areas such as the United 
States.[14]   
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2.3 Thyroid Dysfunction: Diagnostic Definitions 
Serum Thyroid Stimulating Hormone (TSH, also called serum thyrotropin), the 
major regulator of the thyroid, constitutes the single best indicator of its function.[15] 
While technically an indirect reflection of thyroid hormone supply (TSH is a stimulating 
hormone secreted by the pituitary), it is used as the initial and primary diagnostic 
instrument for several reasons.  First, TSH is a central component of the negative-
feedback system that regulates thyroid function. Second, TSH secretion is exquisitely 
sensitive to the plasma concentration of T3 & T4; small changes in serum thyroid function 
cause logarithmic amplification in TSH secretion.[16]  Even minor fluctuations are 
detectable with advanced TSH assays, which are capable of discriminating values as small 
as <0.1mU.[16]  TSH has a sensitivity of ~98% and specificity of ~92% when used to 
confirm clinically suspected thyroid disease by an endocrinologist.[17]  However, its 
accuracy is difficult to ascertain when it is used to screen asymptomatic persons for 
thyroid dysfunction.  
While TSH is often the initial thyroid function test used for screening, an abnormal 
value often prompts subsequent measurement of T4. Unfortunately, the determination 
of a TSH abnormality is not always straightforward. The normal range of serum TSH 
concentration varies slightly in different laboratories (sometimes defined this by a 
population range), but is now most commonly defined as 0.4 to 4.2 mU/L; This is the 
range of TSH prevalence levels in 96% of the disease- and risk-free population.[18]  A 
complicating factor in the identification of thyroid dysfunction is the relative fluidity of 
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what is considered the ‘normal range’ over time. Over the last few decades, the upper 
limit of normal has gradually declined from 7.0-10 mU/L to 4.0–5 mU/L.[19]   
Thyroid dysfunction can be further divided into that which is ‘subclinical’ versus 
‘overt’.  Subclinical dysfunction can best be described as an early condition of mild 
thyroid hormone excess/deficiency in which thyroid hormones remain within the normal 
range.  Subclinical hypothyroidism is characterized by a high serum TSH and a normal 
serum concentration of free T4 (measured as ‘free’ since the total level can be distorted 
by the level of carrier proteins to which thyroid hormones are bound); overt 
hypothyroidism has high TSH and a low free T4 serum concentration.[18]  Subclinical 
hyperthyroidism, on the other hand, is defined by a low TSH and a normal free T4, and 
overt hyperthyroidism is described as a low TSH with a high free T4 serum 
concentration.[11]  These definitions are reflected below in Reference Table 1. Most 
endocrinologists recommend repeat testing for those with lab values consistent with 
subclinical thyroid dysfunction within 2-3 months since borderline values may not reflect 
persistent dysfunction, though the clinical value of this practice is questionable.[19]  
Given the significance of TSH for screening, some researchers and clinicians specify levels 
of that hormone to further define subclinical dysfunction.[18]   
One special combination of abnormal thyroid tests is worth mentioning: 
nonthyroidal illness syndrome (also known as euthyroid sick syndrome) is a condition 
encountered in patients with acute or chronic systemic illness. The laboratory 
parameters that define this syndrome are low T3, low/normal T4 and low/normal TSH. 
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This condition may affect 60 to 70% of critically ill patients, and values generally 
normalize if the illness resolves (thus hinting at a non-thyroidal etiology).[20]  
Reference Table 1: Characterization of Thyroid Dysfunction: Typical Thyroid Function 
Tests 
Disorder TSH Free T4 
Overt 
Hyperthyroidism 
¯ ­ 
Subacute 
Hyperthyroidism 
¯ Normal 
Overt 
Hypothyroidism 
­ ¯ 
Subacute 
Hypothyroidism 
­ Normal 
 
2.4 Thyroid Dysfunction: Incidence & Prevalence 
The global prevalence and incidence of thyroid dysfunction are difficult to 
determine given differences in screening, diagnostic thresholds, assay sensitivities, iodine 
nutrition, etc.[12]  In general, the overall prevalence of hyperthyroidism and 
hypothyroidism ranges from 0.5–4% in iodine-replete communities, and is 5–10 times 
higher in women than in men.[21] In the United States, approximately 0.3% suffer from 
overt hypothyroidism, but 4.3% have mild or subclinical hypothyroidism.[22] 
Hyperthyroidism has a prevalence of 1% to 2% in women and 0.1% to 0.2% in men.[23] 
Most of the studies that have explored the epidemiology of thyroid dysfunction 
do not distinguish between primary thyroid dysfunction and that which is caused by 
other factors. TSH can be depressed, for example, in patients with psychiatric illness, 
non-thyroidal illness syndrome, pregnancy, hypothalamic-pituitary disorders, and among 
those taking certain medications (glucocorticoids, dopamine, somatostatin analogues, 
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amphetamines, dobutamine, bexarotene, bromocriptine).[24]  Robust statistics for 
primary thyroid dysfunction in the population are unknown.  
2.5 Thyroid Dysfunction Screening 
The rationale behind thyroid function testing in asymptomatic individuals is early 
detection and treatment with the hopes of preventing complications arising from thyroid 
imbalance. Specifically, there is hope that screening may prevent morbidity and mortality 
from fractures, cancer, or cardiovascular disease. However, widespread screening and 
subsequent treatment of thyroid dysfunction can also result in harms due to labeling, 
false-positive results, overdiagnosis and overtreatment.  
Appropriate use of thyroid function screening has been much debated, and 
current recommendations are inconsistent across both countries and medical specialties. 
Recently, the United States Preventive Services Task Force (USPSTF) concluded that, for 
nonpregnant, asymptomatic adults, “current evidence is insufficient to assess the balance 
of benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic 
adults.”[25]  The American Academy of Family Physicians has endorsed the USPSTF 
recommendation, but The American Thyroid Association recommends screening at age 
35 years and every 5 years thereafter.[25, 26]  The American Association of Clinical 
Endocrinologists recommends routine TSH measurement in older patients—age not 
specified—especially women.[27]  Until the guidelines recently became ‘inactive’, the 
American College of Physicians recommended screening in women older than age 50 
years with one or more symptoms possibly caused by thyroid disease.[27]  
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Although exact estimates of rates in the United States are unknown, screening for 
thyroid dysfunction by primary care providers seems to be a common practice in the 
developed world.[25]  In the United Kingdom, for instance, an estimated 18-25% of adults 
receive thyroid function assessed annually.[28] 
2.6 Conclusion 
Needless to say, the high prevalence of both thyroid dysfunction and heart failure 
highlight a need for preventive & therapeutic strategies to reduce morbidity, mortality, 
and cost from both of these conditions. The development of such strategies hinges on a 
better understanding both of the mechanisms and of the long-term consequences of one 
on the other.  
Literature Review 
This literature review was conducted using Google Scholar and PubMed. The main 
key words employed in the literature review were: heart failure, heart failure diagnosis & 
management, cardiovascular disease, cardiovascular system, thyroid dysfunction, thyroid 
disease, subclinical thyroid dysfunction, thyroid screening, thyroid hormones, thyroid-
stimulating hormone, hypothyroidism, and hyperthyroidism.  
3.1 Historical Investigation of Thyroid Function & Cardiovascular Health 
The first documented association between thyroid dysfunction and cardiovascular 
health dates back to 1878, when William Greenfield characterized a case of severe 
hypothyroidism occurring with vascular disease.[29]  Following the development of 
radioimmunoassays to estimate TSH in 1965, more quantitative research could be 
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conducted. In 1976 Belgian researchers reported higher rates of coronary artery disease, 
left ventricular hypertrophy and left ventricular dilation in hypothyroid subjects 
compared with a euthyroid group.[13]  But over the years, such associations were not 
found consistently.[30]  And, when a trial of dextrothyroxine (lower activity isomer of T4) 
in male survivors of acute myocardial infarction demonstrated higher mortality and 
increased arrhythmias, clinicians became wary of the cardiovascular consequences of 
hyperthyroidism.[31]  Over the past few decades, more detailed studies have 
demonstrated that even subtle changes in thyroid hormone concentrations (e.g. those 
observed in subclinical hypo or hyperthyroidism) can adversely affect the cardiovascular 
system.[13]  
3.2 Thyroid Hormones & Cardiovascular Physiology 
Many patients with thyroid dysfunction experience some type of cardiovascular 
manifestation, and it is believed that the most serious complications of thyroid disease 
occur as a result of cardiac involvement.[32]  If left untreated, both overtly hypo- and 
hyperthyroidism accelerate the onset of symptomatic cardiovascular disease.[13]  
Thyroid hormone receptors are present throughout the body, including the myocardium 
and vascular tissue, which allow for hormone alterations to affect cardiovascular 
physiology such as chronotropy and inotropy.[13]  Some mechanisms behind thyroid 
hormone’s cardiovascular effects include endothelial dysfunction, dyslipidemia, changes 
in blood pressure, and myocardial systolic and diastolic dysfunction.[13]  
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3.3 Thyroid Dysfunction & Cardiovascular Health 
In hyperthyroid patients, chronotropic effects of thyroid hormones manifest as 
tachycardia and increased risk of atrial fibrillation.[33]  Other effects of excess thyroid 
hormones include increased cardiac output, myocyte hypertrophy, increased left 
ventricular mass, arterial stiffness and left atrial size.[24]  Components that may 
contribute to heart failure include chronotropy, inotropy, and arrhythmogenic activity of 
the pulmonary veins.[11]  
In contrast, hypothyroid patients demonstrate bradycardia and reduced cardiac 
contractility.[33] Hypothyroidism is also associated with reduced cardiac output, heart 
rate, and contractility along with increases in peripheral vascular resistance, diastolic 
blood pressure, cholesterol levels, and carotid intima-media thickness.[34]  Several of 
these factors are likely instrumental in accelerating atherosclerosis.[13]  Changes in 
coagulation parameters observed in hypothyroidism may also contribute to subsequent 
cardiovascular disease.[13]  The most frequent cardiac abnormality seen with 
echocardiogram in individuals with hypothyroidism is diastolic dysfunction owing to 
impaired ventricular filling and relaxation.[13] 
3.4 Subclinical Thyroid Dysfunction & Cardiovascular Health 
Evidence regarding the association between subclinical thyroid dysfunction and 
cardiovascular outcomes is conflicting.[13]  Some studies document positive associations 
with sudden cardiac death[35] and cardiovascular outcomes such as CVD morbidity & 
mortality.[11, 13, 24]  One study found an increase in cardiovascular disease and death in 
hypothyroid patients but not hyperthyroid patients.[21]  Others identify an increase in 
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mortality in hypothyroidism, but no corresponding increase in cardiovascular events.[35]  
To summarize, a multitude of studies have addressed this topic; while many lean towards 
the conclusion that subclinical thyroid disease may be associated with cardiovascular 
morbidity, no cause and effect can be proven in the absence of mechanistic studies and 
randomized clinical trials.[35]  
3.5 Thyroid Dysfunction in Heart Failure 
According to observational studies, subclinical hypothyroidism and nonthyroidal 
illness syndrome are the most frequent thyroid hormone alterations in patients with 
heart failure.[36]  The latter is particularly common and occurs in an estimated 20-30% of 
patients with heart failure.[37]  Unfortunately, both subclinical hypothyroidism and 
nonthyroidal illness syndrome (also called low T3 syndrome) have been associated with a 
poor prognosis.[13] 
3.6 Thyroid Screening in Heart Failure Patients 
Since the physiological effects of thyroid dysfunction on the cardiovascular 
system compromise cardiac function, and since we know thyroid disease may contribute 
to heart failure and can be associated with poor prognosis, thyroid function screening 
was considered by some to be a standard of care for new onset heart failure until 
recently.[11]  The American College of Cardiology, jointly with the American Heart 
Association, first published guidelines for the evaluation and management of HF in 1995. 
In these initial recommendations, TSH was recommended for patients with atrial 
fibrillation or sinus rhythm with unexplained heart failure (class I and class II 
recommendations, respectively).[38]  Subsequent guidelines published in 2001, 2005, 
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2009, and 2013 all recommended the measurement of thyroid function tests (especially 
TSH) in the initial laboratory evaluation of all patients presenting with heart failure (level 
of evidence: C).[39-42]  The most recent guidelines published in 2017, however, do not 
mention thyroid testing.[43]  Still, some highly utilized texts in cardiovascular medicine 
continue to recommend this practice.[5] 
3.7 Conclusion 
The field of cardiology is fortunate to have such an abundance of knowledge on 
standard risk factors and secondary preventive measures for both cardiovascular disease 
and heart failure. However, to address a disease with such a tremendous burden on 
population health, more research is needed to clarify the role of practices such as thyroid 
function screening. Knowing how often thyroid screening is performed, who specifically is 
screened, and what testing uncovers may lead to more targeted, cost-effective screening 
in those who would derive the most benefit from that practice—such knowledge can 
help distinguish whether thyroid function screening in this population constitutes a 
valuable tool that augments patient care or a misuse of healthcare resources.    
Methods 
4.1 Setting 
The University of Kentucky Albert B. Chandler Hospital is a level 1 trauma, 569-
bed acute care hospital located in Lexington, KY; it is part of the UK HealthCare 
enterprise. During the period of 2007-2017, this institution annually processed more than 
30,000 individual inpatient discharges.[44] 
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4.2 Study Design & Sampling 
This study used a clinical cohort to examine the practice of thyroid dysfunction 
screening in adults during their first known hospital admission that included a diagnosis 
of heart failure. Data for the current study were limited to the earliest inpatient hospital 
stay (also referred to as an inpatient encounter) during which heart failure was 
documented as a diagnosis from 2007 through 2017.  
In December 2018, inpatient records among heart failure patients from 2004 to 
2017 in Sunrise Clinical Manager, the electronic medical record used by the University of 
Kentucky inpatient services, were identified. University of Kentucky’s Center for Clinical & 
Translational Science Biomedical Informatics Team extracted from their Enterprise Data 
Warehouse encounters including an ICD9 or ICD10 diagnosis of heart failure.* A diagnosis 
of heart failure during an encounter was identified using the following ICD-9 and ICD-10 
code definitions documented at discharge: ICD-9 code of 428.x in any position and ICD-10 
code of I50.x in any position. Information obtained included basic demographics and 
thyroid function tests. Using the encounter data, the first known inpatient stay 
associated with a documented diagnosis of heart failure was determined. Afterwards, 
first known heart failure admission encounters were narrowed to those taking place from 
2007-2017. This was done for two reasons: first, electronic medical records were 
mandated at UK Healthcare in 2004 and it is possible that adjusting to this system makes 
early data less reliable; second, it allowed for three years of encounters that could help 
                                                        
* The project described was supported by the NIH National Center for Advancing Translational 
Sciences through grant number UL1TR001998.  The content is solely the responsibility of the 
author and does not necessarily represent the official views of the NIH. 
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determine whether an admission from 2007 on was in fact the first heart failure 
hospitalization.[45]  
4.3 Variables & Endpoints 
All information was obtained from structured data elements and included: age at 
the time of encounter, gender, race, ethnicity, and BMI. Additional information included 
admission date, discharge date, presence of previously diagnosed heart failure or thyroid 
disease, prescription for the most common thyroid medications (see separate appendix 
for full list) filled in the past year, and values for the first TSH, Free T3, and Free T4 
obtained during the encounter. Previously diagnosed heart failure was defined as a 
recorded heart failure ICD-9 or ICD-10 diagnosis (defined above) documented prior to the 
encounter—this information included diagnosis codes from inpatient hospital stays as 
well as emergency room visits and the EMR used for UK Healthcare’s outpatient 
encounters [Ambulatory Electronic Health Record (AEHR)].  In a similar manner, 
previously diagnosed thyroid disease was determined by previous documentation of ICD-
9 (240-246) or ICD-10 codes (E00-E07). 
BMI values were categorized according to the common definitions of 
underweight, normal weight, overweight, and obese. Patient age was grouped into the 
following categories: <45, 45-55, 55-64, 65+ years. These age cutoffs were chosen based 
on definitions used in the derivation of premature Coronary Artery Disease and 
Atherosclerotic Cardiovascular Disease (ASCVD).[46, 47] For patients with no race or 
ethnicity documented, a label of ‘unknown’ was assigned.  
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Two outcomes of interest, thyroid function tested and thyroid dysfunction 
(among those tested), were used in separate analyses. To assess correlates of thyroid 
function testing, dichotomous variables were created to indicate whether or not patients 
had TSH performed during the supposed first observed heart failure admission. TSH was 
used both because it is the primary recommendation for initial screening and because 
every patient whose thyroid function was tested had their TSH evaluated. Normal ranges 
for thyroid function tests were chosen based on those used by the UK Healthcare 
chemistry laboratory, which reads the tests in question; They are included in Reference 
Table 2.  
Reference Table 2: Normal Range (Age-based) for Thyroid Function Tests Used in This 
Study[48] 
Thyroid Function Test 
   Age range (years) 
Normal Range 
TSH 
   18-20yo 
   21+ 
 
0.5-4.3 µIU/mL 
0.4-4.2 µIU/mL 
Free T4 
   17+ 
 
0.8-1.7 ng/dL 
Free T3 
   All ages 
 
2.2-4.0 pg/mL  
 
4.4 Data Cleaning 
Once the data were obtained, encounters without a documented date were 
eliminated. In order to restrict the data to inpatient admissions, encounters were limited 
to encounters lasting a duration of 1 day or more.  Redundant entries were pared down; 
any encounters with an identical deidentified encounter ID were merged such that 
thyroid function studies were included. When more than one value for a thyroid function 
study was available for the initial value, the maximum was used. Encounters were 
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eliminated if they did not include a documentation of heart failure during the encounter. 
For each deidentified (unique) medical record number, the earliest of these remaining 
encounters was selected as the initial heart failure admission. Subsequently, encounters 
were eliminated if the patient had a previously documented diagnosis of heart failure or 
thyroid disease. Finally, encounters for patients under 18 years old at the time of 
encounter were removed. 
4.5 Analysis 
Overall, a cross-sectional analytic approach was used on the clinical cohort 
described.  Descriptive statistics were conducted for all encounters and were compared 
for both TSH tested vs not and thyroid dysfunction among those tested vs not. Figures 
were created to visualize both the proportion of TSH testing per year as well as specific 
thyroid function tests ordered for all heart failure encounters.   
Logistic regression analyses were performed to determine correlates of the 
independent variables listed above and whether TSH was tested (dependent variable). 
Thus, odds ratios for the known characteristics were reported. Bivariate analysis of each 
individual variable of interest was conducted first. Whether these variables reached 
significance determined which were included in the complete model. Finally, the model 
was refined with backwards elimination to establish variables in the final model. In this 
way, race, ethnicity, and age were eliminated from the model. Sex, year of encounter, 
and length of stay were retained for the final model.  Models were run with BMI, age, 
and length of stay as both categorical (ordinal) and continuous variables. All three had 
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higher significance levels when modeled as continuous rather than categorical variables. 
Because of this, they were treated as continuous in the final model.  
An identical strategy was used to explore any associations between the 
characteristics measured and thyroid dysfunction (defined by abnormal TSH). The 
dependent variable was dichotomized as TSH normal (within the normal range) vs 
abnormal. Logistic regression was used to estimate odds ratios for thyroid dysfunction 
among those tested for each characteristic measured. Whether these variables reached 
significance determined which were included in the complete model. This model was 
refined with backwards elimination to establish variables in the final model. The final 
dependent variables in the final model were: sex, length of stay, age 65 years +, and 
black/African American race (vs white). 
All analyses were conducted using SAS software, version 9.4 (SAS Institute; Cary, 
NC, USA). 
Results 
5.1 Final Data Set 
Data for 841032 inpatient encounters were collected from 22491 unique patients 
who had heart failure documented at some point between 2004-2018. Exclusion criteria 
were applied to obtain a final data set consisting of 15900 encounters from unique 
patients occurring 2007-2017. These encounters met the criteria of initial heart failure 
encounters in adults with no known thyroid dysfunction. See Figure 1 for more details on 
specific exclusions. 
 23 
Figure 1. Final Data Set Selection Process  
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5.2 Overall Encounter Characteristics 
Tables 1 summarizes patient demographics in all patients encountered. The 
patients were 55% male and 45% female and mean age was 64.8 years (range 18-104). 
The number of participants was highest in the age group 65+ (52.74%), and lowest in the 
group <45 (9.26%). White participants dominated this study (constituting 89.58%); 
black/African American was second most prevalent race (7.43%), with very few others. 
Race was unreported or not provided for 2.3% of encounters. The majority (77.75%) of 
patients were non-Hispanic/Latino and 21.52% were unknown. Only 0.73% were 
Hispanic/Latino. Average BMI was 37.42kg/m2, with the highest percentage of patients 
having a BMI over 30 kg/m2 (41.74%). Average length of stay was 11.17 days, but most 
patients were hospitalized for 1-7 days (56.92%). The proportion of encounters during 
which TSH was tested increased over the study period from 6.18% in 2007 to 13.42% in 
2017.  Prevalence of thyroid screening in our population is presented in Figure 2.  Over 
the study period, 36.09% of newly diagnosed heart failure patients had their TSH checked 
during hospitalization. Further information regarding of specific tests ordered during the 
inpatient encounters is presented in Figure 3.  
5.3 Thyroid Function Screening 
Table 2 reports demographics in patients with thyroid function tested vs not.  
Table 2 also includes results from bivariate logistic regression analysis, including 
unadjusted odds ratios, 95% confidence intervals and p-values to provide associations 
among covariates to thyroid function being tested. Thyroid function testing was 
significantly associated with female sex (p=<.01), length of stay (p=<.01) and year of 
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encounter (p=<.01). Race, ethnicity, and age were not significantly associated with 
thyroid function testing. Table 4 presents the results from multivariable logistic 
regression model for thyroid function testing. Adjusting for other covariates in the model, 
female sex, length of stay, and year of encounter remained significant (all p=<.01) in 
association with thyroid testing.  Female patients had 1.29 times the odds of having their 
TSH tested in comparison to males. With each progressive year, the odds of TSH testing 
in this population increased by 0.03. Finally, the odds of testing increased with each 
subsequent length of stay interval.  
5.4 Thyroid Dysfunction 
Additionally, results are presented for the analysis of tested patients and whether 
they had thyroid dysfunction. Table 3 compares and contrasts demographics between 
tested patients who were found to have dysfunction vs not. Results of bivariate logistic 
regression are also included. Patients who underwent TSH testing were mostly white 
(89.00%) non-Hispanic/Latino (77.59%), slightly more male (51.19%) with a mean age of 
65.08 years. There were no biracial subjects in this group. Mean BMI was 36.13 kg/m2 
and mean length of stay was 13.71 days. Bivariate analysis using the created variable 
‘dysfunction’ suggested that female sex, African American/black and unreported race, 
and length of stay 8-14 or 22+ days were associated with increased thyroid dysfunction 
(p=<.01, .01, .04, .01, <.01 respectively). Age 65+ was associated with decreased odds of 
dysfunction (p=.0459). Year of encounter, BMI, other races, & ethnicity did not show a 
significant association with thyroid dysfunction.  
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Table 5 presents results from multivariate logistic regression model for thyroid 
dysfunction, including the variables of female sex, length of stay (8-14 & 22+ days), 
black/African American race, unreported/refused race, and age. Adjusting for other 
covariates, patients who were female (OR 1.34, p=<.01), or whose hospital stay lasted 8-
14 days or 22+ days (OR 1.2 and 1.45 respectively) had increased odds of thyroid 
dysfunction. The designation of unreported/refused for race lost its significance. In 
analysis adjusted for sex and length of stay, Black/African American patients, had 0.74 
(p=0.01) times the odds of thyroid dysfunction when compared to whites among patients 
with an incident heart failure hospitalization.  Age over 65 was associated with decreased 
risk of thyroid dysfunction (OR: 0.82, p=0.048). 
Discussion 
6.1 Introduction 
To my knowledge, this is the first study to examine frequency of thyroid function 
testing in adult patients admitted to the hospital with heart failure, and the first to 
examine the characteristics of those tested vs not. The purpose of this study was to 
identify the frequency with which adults initially admitted for heart failure had their 
thyroid function checked at the University of Kentucky Albert Chandler hospital over the 
period 2007-2017 and to describe the frequency of thyroid dysfunction observed in those 
patients. 
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6.2 Frequency of Thyroid Function Screening  
Despite the recommendations to screen for thyroid dysfunction in this patient 
population, a minority of patients (36.09%) had their TSH tested in this study. 
Unfortunately, no studies have previously examined thyroid function screening in 
patients with heart failure.  So, it is unclear how these results would compare to a 
broader population.  It may be that many clinicians are carefully considering the lack of 
evidence behind this recommendation (level C) and have largely chosen not to universally 
screen initial heart failure patients. In conjunction with this, providers may be taking into 
account other patient risk factors for heart failure. In a patient with multiple 
comorbidities, they determine that likelihood heart failure is due to thyroid dysfunction is 
low. For patients that tend to receive most of their care within the UK Healthcare system, 
practitioners may deem screening unnecessary if they have been tested relatively 
recently.  
Longer hospital stays were associated with increased odds of testing. (ORs: 1.33, 
1.69, 2.18 for 2, 3, and more than 4 weeks respectively). It is reasonable to (on average) 
consider a longer length of stay indicative of a more severe illness. In such patients, it is 
often practical to ensure no easily treatable contributing factors like thyroid dysfunction 
can be addressed while the patient is in the hospital. A longer length of stay also allows 
for more opportunities for different providers to order thyroid function studies.  
While the magnitude of the association is not particularly strong (OR: 1.03, 95% 
CI: 1.02-1.04), there was a significant increase in testing frequency with each progressive 
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year. This may reflect greater availability of tests, increased ease of ordering, and/or 
better resources with regard to informing providers of ACC recommendations. 
Controlling for length of stay and year, female patients had 1.29 times the odds of 
having their thyroid function screened versus males (95% CI: 1.21-1.38).  We do know 
that females are more likely to suffer from thyroid dysfunction than their male 
counterparts, and this alone may account for more thyroid function testing among 
females.[30]  In other words, providers that recognize gender as a risk factor may 
consider testing to be of higher value in this population. However, it is also true that 
women are underdiagnosed and undertreated with regard to cardiovascular disease, and 
are less likely to receive preventive treatment and guidance than are men at a similar 
ASCVD risk.[49-51]  Because practitioners are less likely to recognize cardiovascular 
disease in women (strongest risk factor for heart failure), they may be searching for an 
alternate etiology.   
6.3 Thyroid Dysfunction Among Screened Patients 
Among the patients screened for thyroid dysfunction, most patients had a TSH 
(72%) within the normal range. In total, 28% of those tested revealed some sort of 
thyroid dysfunction. A study that included hospitalized patients aged 65 or older 
demonstrated 17.4% thyroid dysfunction.[52]  Patients hospitalized with COPD 
exacerbation had 20% abnormal TSH.[53] In patient screened in the CORONA trial (which 
sought to examine the effect of low-dose rosuvastatin on survival in heart failure), 8.7% 
were discovered to have thyroid dysfunction using a broader normal range for TSH.[54] 
Thus, our study suggests thyroid dysfunction may be more prevalent among our group of 
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patients initially diagnosed with heart failure as compared with other hospitalized 
groups—even other groups diagnosed with heart failure.  
The most common thyroid dysfunction among those tested was high TSH with 
normal FT4 (11%). This is concordant with many observational studies which have shown 
this pattern (consistent with subclinical hypothyroidism).[36]  Nonthyroidal illness 
syndrome, another common thyroid hormone disturbance in ill patients, could not be 
adequately evaluated since the TSH values may be normal in this condition and T3 was 
rarely measured.  
Among screened patients, multivariate analysis revealed that female sex (OR: 
1.33, 95% CI: 1.18-1.49) was associated with increased odds of thyroid dysfunction 
(abnormal TSH). This is in agreement with studies that have consistently found 
prevalence of thyroid dysfunction is much higher in females than males in the general 
population.[55, 56]  
To some extent, increasing length of stay was also associated with increased odds 
of thyroid dysfunction (8-14 days and 22+ days OR: 1.20 & 1.45 respectively). 
Interestingly, the 15-21 day range did not reach significance. While dysfunction 
increasing with time could be secondary to longstanding illness, disease severity was not 
ascertained in this study. Since any differential of greater comorbidity among longer 
hospitalization is unknown, this is highly speculative. It is unclear why the middle range 
did not reach significance.  
African American race [vs white], was associated with decreased odds of thyroid 
dysfunction (OR: 0.74, 95% CI: 0.59-0.93). In a large prospective study in Brazil, Olmos, et 
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al. demonstrated that African Americans had less thyroid dysfunction overall, but that 
this was mainly a result of less overt hypothyroidism (OR = 0.76) despite increased overt 
hyperthyroidism (OR = 1.82).[57] While this study did not examine the particular types of 
thyroid dysfunction, it is concordant with this and other studies that conclude African 
Americans have a lower prevalence of thyroid dysfunction as a whole.[17, 58] 
Age was included in the final model since it is consistently associated with thyroid 
dysfunction in the literature.[55, 59]  Multiple studies have shown the incidence and 
prevalence of both hypo and hyperthyroidism increased with age.[60, 61] 
Hypothyroidism, for example, seems to climb with each decade—it ranged from 4 to 21% 
in women and 3 to 16% in men.[62] In our study, only the age range of 65+ showed an 
association with thyroid dysfunction—and this was a negative association. This is 
puzzling, as we would expect the opposite. It is possible that the selection bias inherent 
in studying a disease more common in the elderly has made age as a covariate less 
reliable.  
While race ‘unreported’ [vs white] was initially associated with increased odds of 
thyroid dysfunction, this variable did not maintain significance in the final model (p=.06).  
6.4 Limitations: population, characteristics/measurements, analysis 
Thyroid function screening in newly diagnosed heart failure patients is an 
understudied aspect of heart failure management. Though this study is unique in its 
examination of this issue, it is not without limitations. Encounters were restricted to 
patients admitted to a single hospital within the UK Healthcare setting.  The study 
therefore relied on a small sample of heart failure patients—and ones that are unique to 
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the University of Kentucky. It is only by considering encounters across the whole 
spectrum of acute and chronic care that the full picture of practice and prevalence can be 
captured. Heart failure may be both diagnosed and treated solely in an outpatient 
setting, and these cases are not accounted for in this analysis. In two studies, the 
proportion of heart failure diagnoses occurring in an outpatient setting ranged from 31 to 
42%.[63]  When emergency department visits are included (for patients diagnosed but 
not admitted), the proportion may be as high as 52%.[64]  This study does not capture 
this ‘outpatient’ subset of heart failure patients.  
Misclassification may have occurred since we have very limited data on patients, 
and a validated ascertainment protocol was not utilized. As a result, heart failure 
ascertainment, in particular, may have been very inaccurate. Since any diagnostic 
position was used to define a heart failure encounter, a substantial proportion of the 
primary reason for hospitalization may not have been heart failure-related. And, since 
this data only covers a single EMR, any outside medical care is unaccounted for. We may 
have, for instance, identified an encounter as an initial heart failure encounter when that 
individual simply has chronic heart failure but just recently started receiving care at UK.  
There are innumerable potential confounding factors that this study was unable 
to account for. For example, it was not possible to obtain reliable data on which provider 
ordered the thyroid function tests. It is entirely possible that provider preference is the 
dominant determinant of thyroid function testing. And, while odds ratios suggest that 
differences in patient characteristics between tested and not-tested patients were small, 
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we did not have comprehensive data on comorbidities, family history, or vital signs (just 
to name a few).  
It should be stressed that what constitutes an abnormal TSH level is uncertain. 
Laboratories use reference intervals based on statistical distribution across a population 
rather than based on clinical outcomes, and different TSH cutoffs are used to define 
subclinical thyroid dysfunction in particular.[25]  This study has defined undifferentiated 
thyroid dysfunction using these parameters, and therefore cannot comment on its 
relation to increased risk of adverse outcomes, or on more specific types of thyroid 
dysfunction.  TSH secretion does fluctuate during the day, with peak values in the early 
morning and a nadir in the afternoon.[18]  As the more common lab draws obtained in 
the hospital do occur early in the morning, it is possible that the study has effectively 
over-diagnosed some patients. It is also unknown how many (if any) patients were tested 
based on symptoms rather than blanket screening.  
6.5 Further Comments  
Despite the published recommendation to obtain thyroid function tests 
(especially TSH) since 1995, this study demonstrated that at UK Albert Chandler Hospital, 
obtaining TSH is not very common among HF patients, though testing in this specific 
population may have slightly increased over the study period. While no formal 
explanation was offered, the failure to maintain this recommendation in a 2017 update 
may reflect doubt as to its cost-efficacy and value to patient care.  
Proponents of screening claim that erring on the side of caution to detect a 
treatable condition is the prudent choice—particularly since overt thyroid dysfunction is 
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associated with adverse sequelae such as increased bone turnover, osteoporosis, and 
fractures.[24]  Furthermore, studies have shown that in-hospital TSH values are highly 
concordant with ambulatory values in patients over 65 (our main heart failure 
population), and thus may not need to be repeated prior to initializing treatment.[52] 
While there is some evidence from prospective studies that even subclinical 
hypothyroidism and congestive heart failure are correlated, questions remain: which 
comes first, when do we treat, does screening improve patient outcomes, and is it cost 
effective.[65] 
At this time, the benefit of thyroid function testing both in the general population 
and in heart failure patients is unknown. Furthermore, epidemiological evidence 
supporting treatment of subclinical dysfunction especially is limited and results are 
mixed.[25]  
Not only are ‘normal ranges’ of TSH unknown, currently there is a lack of 
consensus on when treatment for thyroid dysfunction (subclinical especially) is indicated. 
[25]  This is true of the general populace as well as those hospitalized with heart failure. 
So to a certain extent screening is of limited value.  Finally, it is important to think of all 
possible consequences of screening. For example, a large magnitude of overdiagnosis 
and overtreatment likely follows from screening asymptomatic individuals. USPSTF aptly 
states that “overdiagnosis leads to psychological consequences and unnecessary 
treatment…it should be avoided in disease prevention and health promotion.”[25]  
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6.6 Next Steps 
More research is needed in this area. Specifically, studies need to evaluate harms 
and benefits of thyroid screening in heart failure patients in order to establish whether 
the practice confers a health benefit. Studies are also needed to explore what TSH values 
should serve as clinically meaningful cutoffs for diagnosis and treatment. Finally, we need 
to investigate long-term outcomes of thyroid dysfunction in heart failure patients. 
6.7 Conclusions 
Despite progress made in the management of heart failure, this syndrome is still 
associated with poor clinical outcomes including a high risk of mortality.[11]  Its burden 
on the healthcare system is high—heart failure was responsible for an estimated 31 
billion dollars of health care expenditure in 2012 (not counting indirect costs & loss of 
productivity).[1]  Its costs are projected to increase by 46% by 2030. Nearly 80% of the 
projected expenses are attributable to increased hospitalizations.[10]  In order to reduce 
hospitalizations and related costs, management strategies should be based on high-
quality evidence.  Gaining better understanding of all factors that contribute to heart 
failure can help formulate interventions aimed at decreasing incidence, prevalence, and 
the burden of heart failure on our healthcare system. In the same vein, it is important to 
recognize which steps can be taken to reduce costs during heart failure hospitalizations 
and avoid harms of interventions. Thyroid function screening is a practice that is 
commonly performed in heart failure patients despite lacking evidence on improved 
outcomes. More research is needed to determine how screening is used and what 
population it is most likely to benefit. 
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This study explored the use of thyroid function screening in newly diagnosed 
heart failure patients hospitalized at the University of Kentucky Albert B. Chandler Hospital 
from 2007-2017. The results suggest that, despite recommendations, only a minority of 
newly diagnosed heart failure patients who are hospitalized have their thyroid function 
screened. Furthermore, our data hint that thyroid function is not consistently tested on all 
heart failure patients but is tested more often in women and patients with longer 
hospitalizations.  Screening also increased over time. Among those screened, thyroid 
dysfunction appeared to be more common than that reported in the general population but 
was still a minority of patients. The most common abnormality detected was subclinical 
hypothyroidism. We hope that knowing how often thyroid screening is performed, who 
specifically is screened, and what testing uncovers may lead to more targeted, cost-effective 
screening in those who would derive the most benefit from that practice. 
Further studies should investigate the role of thyroid dysfunction across the 
natural history of cardiovascular disease in general (and heart failure specifically) to gain 
a better understanding of the underlying mechanisms. Not only are studies needed to 
clarify the benefits and harms of screening in this population, but randomized controlled 
trials should be conducted to demonstrate benefit of treatment and establish an 
evidence-based threshold for treatment.  
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Appendix 
 
Table 1. Characteristics of Adult Patients During First Known Hospital Admission with 
Documentation of Heart Failure at the University of Kentucky Albert B. Chandler Hospital 
from 2007-2017 
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Table 2. Bivariate Analysis of Patient Encounter Characteristics and Thyroid Screening for 
Adult Patients During First Known Hospital Admission with Documentation of Heart 
Failure at the University of Kentucky Albert B. Chandler Hospital from 2007-2017 
Characteristic 
 
TOTAL N=15900 
Thyroid 
function not 
tested 
N=10162 
(63.91%) 
Thyroid 
function 
tested 
N=5738 
(36.09%) 
Crude 
Odds 
Ratio 
95% CI p- value 
Sex 
   Male 
   Female 
- 
5795 (57.03) 
4367 (42.97) 
- 
2937 (51.19) 
2801 (48.81) 
- 
Ref 
1.27 
- 
Ref 
1.19,1.35 
- 
Ref 
<.0001 
Race 
   White 
   Black/African American 
   Asian 
   Spanish American 
   American Indian/Alaskan 
   Middle Eastern 
   Hawaiian/Pacific Islander 
   Bi-racial 
   Unreported/Refused 
- 
9136 (89.90) 
724 (7.12) 
20 (0.20) 
24 (0.24) 
9 (0.09) 
9 (0.09) 
4 (0.04) 
3 (0.03) 
228 (2.24) 
- 
5107 (89.00) 
457 (7.96) 
20 (0.35) 
14 (0.24) 
5 (0.09) 
1 (0.02) 
2 (0.03) 
0 (0.00) 
132 (2.30) 
- 
Ref 
1.13 
1.79 
1.04 
0.99 
0.20 
0.89 
* 
1.01 
- 
Ref 
1.00,1.28 
0.96,3.33 
0.54,2.02 
0.33,2.97 
0.03,1.57 
0.16,4.89 
* 
0.82,1.26 
- 
Ref 
0.051 
0.07 
0.90 
0.99 
0.13 
0.90 
* 
0.90 
Ethnicity 
  Non-Hispanic/Latino 
  Hispanic/Latino 
  Unreported/Refused 
- 
7910 (77.84) 
65 (0.64) 
2187 (21.52) 
- 
4452 (77.59) 
51 (0.89) 
1235 (21.52) 
- 
Ref 
1.39 
1.00 
- 
Ref 
0.96,2.02 
0.93,1.09 
- 
Ref 
0.08 
0.93 
Age at admission 
   <45 
   45-54 
   55-64 
   65+ 
- 
931 (9.16) 
1452 (14.29) 
2476 (24.37) 
5303 (52.18) 
- 
541 (9.43) 
750 (13.07) 
1364 (23.77) 
3083 (53.73) 
- 
Ref 
0.80 
0.95 
1.00 
- 
Ref 
0.77,1.02 
0.84,1.07 
0.89,1.12 
- 
Ref 
0.09 
0.40 
0.99 
BMI 
   < 18.5 
   18.5–24.9 
   25-29.9 
   30+ 
   Unknown 
- 
381 (3.75) 
2282 (22.46) 
2481 (24.41) 
4222 (41.55) 
796 (7.83) 
- 
205 (3.57) 
1297 (22.60) 
1436 (25.03) 
2414 (42.07) 
386 (6.73) 
- 
Ref 
1.06 
0.98 
1.06 
0.90 
- 
Ref 
0.88,1.27 
0.90,1.29 
0.89,1.27 
0.73,1.11 
- 
Ref 
0.56 
0.43 
0.50 
0.33 
Length of stay (days) 
   1-7 days 
   8-14 days 
   15-21 days 
   22+ 
- 
6223 (61.24) 
2113 (20.79) 
801 (7.88) 
1025 (10.09) 
- 
2827 (49.27) 
1278(22.27) 
616 (10.74) 
1017 (17.72) 
- 
Ref 
1.33 
1.69 
2.18 
- 
Ref 
1.22,1.45 
1.51,1.90 
1.98,2.41 
- 
Ref 
<.0001 
<.0001 
<.0001 
Year of encounter 
   2007 
   2008 
   2009 
   2010 
   2011 
   2012 
   2013 
   2014 
- 
670 (6.59) 
593 (5.84) 
669 (6.58) 
816 (8.03) 
874 (8.60) 
804 (7.91) 
915 (9.00) 
1118 (11.00) 
- 
313 (5.45) 
321 (5.59) 
319 (5.56) 
418 (7.28) 
552 (9.62) 
485 (8.45) 
457 (7.96) 
529 (9.22) 
- 
1.03 
- 
1.02,1.04 
- 
<.0001 
 38 
   2015 
   2016 
   2017 
1225 (12.05) 
1222 (12.03) 
1256 (12.36) 
658 (11.47) 
808 (14.08) 
878 (15.30) 
*Numbers too small to estimate a stable OR
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Table 3. Bivariate Analysis of Adult Patients Screened for Thyroid Dysfunction During 
First Known Hospital Admission with Documentation of Heart Failure at the University of 
Kentucky Albert B. Chandler Hospital from 2007-2017 
*Numbers too small to estimate stable OR 
Characteristic 
 
TOTAL N=5738 
No Thyroid 
Dysfunction 
N=4133 (72.03%) 
Thyroid 
Dysfunction 
N= 1605 (27.97%) 
Crude 
Odds 
Ratio 
 
95% CI 
 
p- value 
Sex 
   Male 
   Female 
- 
2197 (53.16) 
1936 (46.84) 
- 
740 (46.11) 
865 (53.89) 
- 
Ref 
1.33 
- 
Ref 
1.18,1.49 
- 
Ref 
<.0001 
Race 
   White 
   Black/African American 
   Asian 
   Spanish American 
   American Indian/Alaskan 
   Middle Eastern 
   Hawaiian/Pacific Islander 
   Bi-racial 
   Unreported/Refused 
- 
3662 (88.60) 
354 (8.57) 
18 (0.44) 
9 (0.22) 
5 (0.21) 
0 (0) 
1 (0.02) 
0 (0) 
84 (2.03) 
- 
1445 (90.03) 
103 (6.42) 
2 (0.12) 
5 (0.31) 
0 (0) 
1 (0.06) 
1 (0.06) 
0 (0) 
48 (2.99) 
- 
Ref 
0.74 
0.28 
1.41 
* 
* 
2.53 
* 
1.45 
- 
Ref 
0.59,0.93 
0.07,1.22 
0.47,4.21 
* 
* 
0.16,40.54 
* 
1.01,2.08 
- 
Ref 
0.01 
0.09 
0.54 
* 
* 
0.51 
* 
0.04 
Ethnicity 
  Non-Hispanic/Latino 
  Hispanic/Latino 
  Unreported/Refused 
- 
3230 (78.15) 
40 (0.97) 
863 (20.88) 
- 
1222 (76.14) 
11 (0.69) 
372 (23.18) 
- 
Ref 
0.73 
1.14 
- 
Ref 
0.37,1.42 
1.00,1.31 
- 
Ref 
0.35 
0.06 
Age at admission 
   <45 
   45-54 
   55-64 
   65+ 
- 
371 (8.98) 
544 (13.16) 
977 (23.64) 
2241 (54.22) 
- 
170 (10.59) 
206 (12.83) 
387 (24.11) 
842 (52.46) 
- 
Ref 
0.83 
0.86 
0.82 
- 
Ref 
0.65,1.05 
0.70,1.07 
0.67,1.00 
- 
Ref  
0.12 
0.19 
0.0495 
BMI 
   < 18.5 
   18.5–24.9 
   25-29.9 
   30+ 
   Unknown 
- 
140 (3.39) 
934 (22.60) 
1052 (25.45) 
1745 (42.22) 
262 (6.34) 
- 
65 (4.05) 
363 (22.60) 
384 (23.93) 
669 (41.68) 
124 (7.73) 
- 
Ref 
0.81 
0.77 
0.81 
0.97 
- 
Ref 
0.59,1.13 
0.55,1.06 
0.59,1.10 
0.67,1.41 
- 
Ref 
0.22 
0.11 
0.18 
0.88 
Length of stay (days) 
   1-7 days 
   8-14 days 
   15-21 days 
   22+ 
- 
2110 (51.05) 
905 (21.90) 
439 (10.62) 
679 (16.43) 
- 
717 (44.67) 
373 (23.24) 
177 (11.03) 
338 (21.06) 
- 
Ref 
1.21 
1.187 
1.47 
- 
Ref 
1.05,1.41 
0.98,1.44 
1.25,1.71 
- 
Ref 
0.01 
0..08 
<.0001 
Year of encounter 
   2007 
   2008 
   2009 
   2010 
   2011 
   2012 
   2013 
   2014 
   2015 
   2016 
   2017 
- 
221 (5.35 
237 (5.73) 
220 (5.32) 
323 (7.82) 
413 (9.99) 
350 (8.47) 
331 (8.01) 
368 (8.90) 
469 (11.35) 
567 (13.72) 
634 (15.34) 
- 
92 (5.73) 
84 (5.23) 
99 (6.17) 
95 (5.92) 
139 (8.66) 
135 (8.41) 
126 (7.85) 
161 (10.03) 
189 (11.78) 
241 (15.02) 
244 (15.20) 
- 
1.01 
- 
0.992,1.030 
- 
0.25 
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Table 4. Logistic Regression of Patient Characteristics for Thyroid Function Screening 
Among Adult Patients During First Known Hospital Admission with Documentation of 
Heart Failure at the University of Kentucky Albert B. Chandler Hospital from 2007-2017 
 
Characteristic Adjusted OR 95% CI p-value 
 
Sex 
   Male 
   Female 
- 
Ref 
1.29 
- 
Ref 
1.22,1.39 
- 
Ref 
<.0001 
Year of Encounter 1.03 1.02,1.04 <.0001 
Length of Stay (days) 
   1-7 days 
   8-14 days 
   15-21 days 
   22+ 
- 
Ref 
1.32 
1.69 
2.21 
- 
Ref 
1.22,1.44 
1.51,1.89 
2.01,2.44 
- 
Ref 
<.0001 
<.0001 
<.0001 
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Table 5. Logistic Regression of Patient Characteristics for Thyroid Dysfunction Among 
Adult Patients Screened for Thyroid Dysfunction During First Known Hospital Admission 
with Documentation of Heart Failure at the University of Kentucky Albert B. Chandler 
Hospital from 2007-2017 
 
Characteristic Adjusted OR 95% CI p-value 
Sex 
   Male 
   Female 
- 
Ref 
1.35 
- 
Ref 
1.20,1.51 
- 
Ref 
<.0001 
Length of Stay (days) 
   1-7 days 
   8-14 days 
   15-21 days 
   22+ 
- 
Ref 
1.20 
1.18 
1.45 
- 
Ref 
1.03,1.39 
0.97,1.43 
1.23,1.70 
- 
Ref 
0.02 
0.10 
<.0001 
Race 
   White 
   Black/African American 
   Unreported/Refused 
- 
Ref 
0.74 
1.41 
- 
Ref 
0.59,0.93 
0.98,2.02 
- 
Ref 
0.01 
0.06 
Age at admission 
   <45 
   45-54 
   55-64 
   65+ 
- 
Ref 
0.86 
0.88 
0.82 
- 
Ref 
0.67,1.09 
0.70,1.09 
0.67,0.998 
- 
Ref 
0.21 
0.24 
0.048 
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Figure 2. Thyroid Function Testing Over Time for Adult Patients During First Known 
Hospital Admission with Documentation of Heart Failure at the University of Kentucky 
Albert B. Chandler Hospital from 2007-2017 
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Figure 3. Specific Thyroid Function Studies Performed on Adult Patients Screened for 
Thyroid Dysfunction During First Known Hospital Admission with Documentation of Heart 
Failure at the University of Kentucky Albert B. Chandler Hospital from 2007-2017 
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Figure 4. Thyroid Dysfunction Detected Among Those Patients Screened for Thyroid 
Dysfunction During First Known Hospital Admission with Documentation of Heart Failure 
at the University of Kentucky Albert B. Chandler Hospital from 2007-2017 
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Figure 5. Hospitalizations Associated with Heart Failure as a Percentage of Total 
Discharges at the University of Kentucky Albert B. Chandler Hospital from 2007-2017 
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